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Abstract
EWI-2, a cell surface IgSF protein, is highly expressed in normal human brain but is considerably diminished in
glioblastoma tumors and cell lines. Moreover, loss of EWI-2 expression correlated with a shorter survival time
in human glioma patients, suggesting that EWI-2 might be a natural inhibitor of glioblastoma. In support of this
idea, EWI-2 expression significantly impaired both ectopic and orthotopic tumor growth in nude mice in vivo.
In vitro assays provided clues regarding EWI-2 functions. Expression of EWI-2 in T98G and/or U87-MG malignant
glioblastoma cell lines failed to alter two-dimensional cell proliferation but inhibited glioblastoma colony formation
in soft agar and caused diminished cell motility and invasion. At the biochemical level, EWI-2 markedly affects the
organization of four molecules (tetraspanin proteins CD9 and CD81 and matrix metalloproteinases MMP-2 and MT1-
MMP), which play key roles in the biology of astrocytes and gliomas. EWI-2 causes CD9 and CD81 to become more
associated with each other, whereas CD81 and other tetraspanins become less associated with MMP-2 and MT1-
MMP. We propose that EWI-2 inhibition of glioblastoma growth in vivo is at least partly explained by the capability of
EWI-2 to inhibit growth and/or invasion in vitro. Underlying these functional effects, EWI-2 causes a substantial mo-
lecular reorganization of multiple molecules (CD81, CD9, MMP-2, and MT1-MMP) known to affect proliferation and/
or invasion of astrocytes and/or glioblastomas.
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Introduction
Malignant gliomas constitute most primary brain tumors. Along with
high proliferative capacity, invasiveness, and resistance to conventional
therapies, they are characterized by a progressive rise in the number
and nature of cytogenetic aberrations [1]. For multiple reasons, we con-
sidered that EWI-2, a cell surface transmembrane protein in the im-
munoglobulin superfamily [2], might affect glioma tumor biology.
First, mRNA for EWI-2 is more elevated in brain than in any other
adult human tissue [2]. Second, EWI-2 affects the motility and mor-
phology of multiple distinct tumor cell types [3–5]. Third, EWI-2 as-
sociates closely with two proteins (tetraspanins CD9 and CD81) that
have previously been linked to astrocyte-astrocytoma tumor pro-
gression and/or proliferation. Whereas CD9 expression correlates with
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astrocytic tumor malignancy [6], CD81 is highly expressed on normal
astrocytes and regulates neuron-induced astrocytic cell cycle arrest and
differentiation [7]. Consequently, CD81 null mice in mixed genetic
backgrounds have enlarged brains owing tomore astrocytes [8]. Further-
more, CD9 affects epidermal growth factor receptor ligand binding
activities of the membrane-bound forms of transforming growth fac-
tor α and heparin-binding EGF-like growth factor [9,10], two mole-
cules that contribute to human malignant glioma cell growth, most
likely through juxtacrine and autocrine mechanisms [6,11,12].
Tetraspanins such as CD9 and CD81 influence motility and pro-
liferation of normal cells and the metastatic functions and tumorige-
nicity of malignant cells [13,14]. To accomplish these actions, they
do not typically serve as cell surface receptors, but rather function,
together with laterally associated partner proteins (e.g., EWI-2, integ-
rins, other tetraspanins), in the context of tetraspanin-enriched micro-
domains (TEMs) [15] on the cell surface. Changes in the protein
content of TEMs can be seen as cells differentiate and/or progress to-
ward a malignant state [16,17]. EWI-2, a major protein partner for
CD9 and CD81 tetraspanins, had not been shown previously to affect
tumor behavior in vivo. Here, we show that EWI-2 is substantially
downregulated on glioblastomas compared to normal brain. Further-
more, EWI-2 expression inhibits glioblastoma tumor growth in vivo
while also inhibiting three-dimensional growth and invasion and mi-
gration in vitro. These inhibitory effects are accompanied by reorgani-
zation of tetraspanin-enriched membrane microdomain components
(i.e., CD9 and CD81) as well as matrix metalloproteinases (i.e.,
MMP-2 and MT1-MMP) on the surface of glioblastoma cells.
Materials and Methods
Plasmids and Reagents
Monoclonal antibodies (mAbs) to CD9 (ALB6; Beckman Coulter,
Hialeah, FL), CD63 (6H1), CD81 (M38), CD82 (M104), CD151
(5C11), MHC class I (W6/32), CD147 (8G6), and EWI-2 polyclonal
antibodywere referenced previously [3,4]. Anti–EWI-2mAb 8A12 [18]
was a gift from Dr. E. Rubinstein. The M2 anti-FLAG mAb, horse-
radish peroxidase–conjugated goat antimouse polyclonal antibody and
nonimmune mouse IgG were from Sigma (St. Louis, MO). C-terminal
FLAG-tagged EWI-2 and CD2 were described [2,3].
Gene Expression Data Analysis
Primary gene expression data were downloaded from the Gene Ex-
pression Omnibus Web site (http://www.ncbi.nlm.nih.gov/geo/) and
used as is. From these data [19,20], notched box-and-whisker graphs
were generated using the R graphics module (http://www.r-project.
org/). The Henry Ford GEO Data Set (GSE4290, top panel ) in-
cludes MAS5 signal intensities for nontumor and grades II to IV glio-
blastoma samples [20]. The Stanford GEO Data Set (GSE2223) is a
log2 Cy5/Cy3 ratio for normal brain reference samples and grades II
to IV glioblastoma samples [21,22]. For genes with multiple probes,
data from all probes are included. Dashed lines indicate the median
of all probes across all samples in each data set. Notches indicate 95%
confidence intervals surrounding the median (dark line). The boxes
denote the 25th to 75th percentiles, and the whiskers extend to 1.5
times the interquartile range of the data. Outliers are indicated as
open circles. Significance was calculated by 2-tailed Welch’s T-test.
Cell Culture and Retroviral Transduction
The human glioblastoma cell lines T98G and U87-MG (American
Type Culture Collection (ATCC), Manassas, VA) and FNX-ampho
packaging cells (ATCC) weremaintained inDulbecco’s modified Eagle’s
medium (DMEM) with 10% fetal bovine serum (Invitrogen, Carlsbad,
CA). Transient transfection of FNX-ampho cells and retroviral infec-
tion of T98G and U87-MG cells were performed as described [23].
Stable infectants were selected in a medium containing 200 μg/ml zeo-
cin (Invitrogen) and were maintained as a polyclonal cell population.
The U87-MG cells expressing luciferase-neomycin phosphotransferase
(neo) fusion protein (U87-LucNeo cells) were previously described [24].
Metabolic Labeling, Immunoprecipitation, Immunoblot
Analysis, and Zymography
For [3H]palmitate labeling, U87-LucNeo cells at 80% to 90% con-
fluence were serum-starved for 2 hours and then pulsed for 2 hours in
medium containing 0.2 mCi/ml [3H]palmitic acid (NEN Bioscience,
Boston, MA) and 5% dialyzed FBS (Invitrogen). Metabolic labeling
with [3H]palmitate is an effective means of analyzing TEMs, which
are palmitate-enriched [25]. Cells were then lysed in 1% Brij 99,
and immunoprecipitations were carried out as described [3]. Proteins
resolved by SDS-PAGE were transferred to polyvinylidene fluoride
membrane (BioRad Laboratories, Hercules, CA) and exposed to Bio-
Max MS film (Kodak, Rochester, NY) at −80°C with an intensifying
screen, to detect [3H]labeling. Nonradioactive samples were transferred
to nitrocellulose membrane and immunoblotted as described [3].
A phosphoimager machine (Storm 860; Molecular Dynamics, Co.,
Sunnyvale, CA) together with ImageQuant v.1.2. program was used
for densitometric scanning of selected protein bands.
For gelatin zymography, serum-free conditioned media from U87-
LucNeo cells or washed beads containing purified protein complexes
were mixed with SDS sample buffer and separated on 10% SDS-
PAGE copolymerized with 1 mg/ml gelatin (Sigma). Zymograms
were then washed twice in 50 mM Tris-HCl, 5 mM CaCl2, pH 8.0,
and 2.5% Triton X-100 for 1 hour and then incubated in 50 mM Tris-
HCl, pH 7.5, 5 mM CaCl2 overnight at 37°C. Gels were stained with
Coomassie brilliant blue, and densitometry was performed on inverted
(black on white) images as mentioned in the previous paragraph.
Cell Proliferation, Chemotactic Migration, and Matrigel
Invasion Assays
To assess proliferation, cells (5 × 104) were plated in triplicate wells
of 24-well plates and then, at various times, were fixed and stained
with methylene blue, extracted, and quantitated at OD of 650 nm.
For migration and Matrigel invasion assays, BD BioCoat growth fac-
tor reduced Matrigel invasion chambers (BD Biosciences, Bedford,
MA) were used according to the manufacturers’ instructions. Briefly,
the transwell membrane filter inserts (6.5 mm in diameter, 8-μm
pore size, 10-nm-thick polycarbonate membrane), either coated
with Matrigel (invasion assays) or uncoated (migration assays), were
placed in a 24-well tissue culture plates. Cells (3 × 104) suspended
in serum-free DMEM containing 0.1% heat-inactivated BSA, were
added to top chambers in triplicate, and DMEM containing 10%
FBS was added to each bottom chamber. After an overnight incuba-
tion at 37°C, nonmigrating cells were removed from the upper face
of the filter using cotton swabs, and cells on the lower filter surface
were fixed and stained with Diff-Quick (Baxter Healthcare Corp.,
McGraw Park, IL). The number of cells per field was counted under
a light microscope.
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Soft Agar and In Vivo Tumor Growth Assays
T98G and U87-MG cells were plated, in six-well plates, in 0.35%
agar in complete medium over a solid underlay of 0.55% agar. Col-
onies were counted after 3 to 4 weeks at 37°C in humidified condi-
tions. To assess ectopic growth, T98G cells (4 × 106 cells per flank in
1:1 mixture of RPMI media were injected subcutaneously into both
flanks of irradiated (4.5 Gy of total body radiation) male nude mice
(Taconic, Germantown, NY). Tumors were monitored for 3 months
and measured with calipers weekly.
Intracranial orthotopic xenografts were established by implanting
50,000 U87-LucNeo cells (± EWI-2) as described [24]. At 6- to 8-day
intervals, mice were anesthetized, injected with D-luciferin and im-
aged with the IVIS Imaging System (Xenogen, Alameda, CA), as de-
scribed [24]. All animal procedures were approved by the Dana-Farber
Cancer Institute Animal Care and Use Committee.
Immunohistochemistry of Xenograft and Human
Brain Samples
Primary human glioblastoma tumors (BT34, BT70, BT74, and
BT79) were propagated in SCID mice in the brain and subcutane-
ously as described elsewhere [26]. These xenografts have the same
genetic and immunohistochemical characteristics of the original tu-
mor as reported in the literature [26,27] and confirmed in our own
laboratory (S.K., unpublished results). Histologic screening of xeno-
graft tumors (both primary and U87-MG cell lines) was performed
by serial analysis of hematoxylin and eosin coronal sections taken at
∼5-mm intervals along the entire brain. Normal brain samples were
obtained from autopsy cases at Brigham and Women’s Hospital. Col-
lection and use of fresh and discarded human tumor tissue was ap-
proved through Brigham and Women’s Hospital Institutional Review
Board. Immunohistochemistry was performed according to standard
protocols [28]. Rabbit anti–EWI-2 polyclonal antibody was incu-
bated at 1:10,000 dilution for ∼10 hours at 4°C. After incubation
with peroxidase-conjugated secondary antibody for 45 minutes, per-
oxidase substrate (diaminobenzidine) was added for 5 minutes, and
slides were counterstained with Mayer’s hematoxylin for 2 minutes.
Statistics
Unless otherwise indicated, graphs showmeans ± SD and significance
was calculated by 2-tailed Student’s T-test, with unequal variance.
Results
EWI-2 Is Present in Normal Brain But Lost in
Human Gliomas
In two independent human data sets, EWI-2 (IGSF8) mRNA was
considerably diminished in grade II, grade III astrocytic tumors, and
most significantly in grade IV astrocytoma, compared to normal
brain (Figure 1A, top and bottom panels). Conversely, another mem-
ber of the EWI protein family, EWI-F, was elevated in each type of
astrocytoma, with the effect most obvious in grade IV glioblastoma
(Figure 1A). In the same data sets, two other members of the EWI
protein family (EWI-3 and EWI-101) and tetraspanin proteins (CD9
and CD81) were increased only slightly in high-grade astrocytic
tumors compared to normal brain tissue (Figure W1). Another tetra-
spanin protein, CD151, which can associate indirectly with EWI-2
[4], was substantially increased in grade IV glioblastoma (Figure W1).
In other experiments, EWI-2 mRNA was highly expressed through-
out adult human brain (Figure W2), and abundant EWI-2 protein
was stained in normal human brain (Figure 1B, e), especially in the
cortex (c) more so than in white matter (w). By contrast, primary
human glioblastoma tumors, propagated in mouse brains, showed
minimal staining for EWI-2 (Figure 1B, c and f ). Tissue sections in
subpanels c and f of Figure 1B are representative of results from four
different human glioblastoma tumors and subpanel e is representative
of three different normal human brain samples. In control experiments,
U87 tumors in mouse brain did not stain for EWI-2 (Figure 1B, a),
whereas EWI-2–transfected U87 tumors were strongly positive
(Figure 1B, d). Background staining with negative control antibody
is shown for normal human brain (Figure 1B, b). Furthermore,
EWI-2 protein, detected using anti–EWI-2 antibodies, is well ex-
pressed in normal human astrocytes in culture within total lysate
(Figure W3A) and on the cell surface (Figure W3B). EWI-2 protein
is also abundant in normal brain cortex, hippocampus, and cere-
bellum, as shown elsewhere [29–31]. Conversely, EWI-2 protein ex-
pression was undetectable in total cell lysate from glioblastoma
cell lines U87 and T98G, unless cells had been transfected (Fig-
ure W3C ). Similarly, EWI-2 protein was minimally detected on the
surface of four different glioblastoma cell lines (Figure W4A) but could
be seen on other cell types (Figure W4B). A summary of EWI-2 ex-
pression results (Table W1) indicates that EWI-2 RNA and protein
is abundant in normal brain and in normal astrocytes. Conversely,
EWI-2 RNA and protein is essentially absent from glioblastoma tu-
mors and cell lines. From these results, we hypothesized that EWI-2
may inhibit astrocytoma growth in vivo. As an initial test of this
hypothesis, Kaplan-Meier survival curves were generated from a com-
bined grade III and grade IV glioblastoma patient data set. As indi-
cated (Figure 1C ), patients with low EWI-2 expression showed
significantly diminished survival. Similar trends were seen when grade
III and grade IV data sets were analyzed separately, although statistical
significance was not achieved owing to the smaller numbers in each
group (Figure W5).
EWI-2 Reexpression Inhibits Astrocytoma Growth In Vivo
To test more directly for possible in vivo antitumor effects of EWI-
2, we expressed EWI-2 in T98G glioblastoma cells at a moderate
level comparable that naturally occurring in HeLa cells (Figure W4B).
Control and EWI-2–transfected cells were then injected subcutane-
ously into nude mice. Cells expressing CD2 or vector control formed
tumors in ∼50% of the mice, within 45 days. However, no tumors
were observed (in eight mice), even after 90 days, when EWI-2 was
present (Figure 2A). Having observed EWI-2 inhibition of glioblas-
toma growth in this preliminary subcutaneous xenograft model, we
then proceeded to test EWI-2 effects in an orthotopic tumor growth
model. U87-LucNeo cells expressing either control vector, or EWI-2,
were injected intracranially, and tumor growth was quantified over
time by noninvasive imaging of tumor-associated bioluminescence.
Bioluminescence imaging is rapid, nonlethal, noninvasive, and closely
correlated with volumetric measurements [24]. Every control mouse
showed detectable tumor growth, as recorded by in vivo imaging
(Figure 2B). By contrast, few tumors were seen in mice injected with
U87-LucNeo/EWI-2 cells, and those seen were generally smaller
(Figure 2B). Quantitation of results from three independent experi-
ments confirmed that EWI-2, during a 20- to 40-day period, markedly
suppressed orthotopic tumor formation by U87-LucNeo cells in mice
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(Figure 2C ). Analysis of tissue slices from injected mice confirmed the
bioluminescence imaging results. For example, in Figure 2C , experi-
ment 3, tumors were present in 10 of 10 brains injected with control
U87-LucNeo cells, whereas only 8 of 15 brains showed tumors on
U87-LucNeo/EWI-2 injection, and those tumors were smaller. Repre-
sentative brain sections from eight mice are shown in Figure W6. As
indicated in Figure 2D, EWI-2 was expressed on the cell surface of
U87-LucNeo cells at a level only 4.3-fold greater than endogenous
EWI-2. Hence, excessive overexpression does not explain the effects
of EWI-2 on orthotopic U87-LucNeo cell growth.
EWI-2 Inhibition of Glioblastoma Cell Functions In Vitro
To gain insight into how EWI-2 might be functioning in vivo, we
carried out relevant in vitro assays using glioblastoma-derived cell
lines T98G and U87-MG (or U87-LucNeo). Compared to controls,
EWI-2 did not affect U87-LucNeo cell proliferation in vitro during a
2- to 6-day interval (Figure 3A). However, anchorage-independent
growth in soft agar is typically seen as an assay more relevant to
the in vivo behavior of transformed cells. In soft agar, both T98G
and U87-MG cells showed significantly reduced colony forma-
tion on expression of EWI-2 but not vector or CD2 control protein
(Figure 3B). Hence, EWI-2 can at least partially affect anchorage-
independent growth of glioblastoma cells. Cell invasion and migra-
tion is also relevant to the progression of glioblastoma in vivo [32].
In this regard, expression of EWI-2 significantly diminished U87-
LucNeo cell invasion and chemotactic migration 45% and 30%, re-
spectively (Figure 3C ). Hence, combined effects of EWI-2 on both
anchorage-independent growth and tumor invasion/migration may
explain glioblastoma inhibition in vivo.
Figure 1. EWI-2 expression in human astrocytoma and normal brain. (A) EWI gene expression in normal human brain and astrocytoma
(grades II, III, IV) samples. The Henry Ford GEO Data Set (GSE4290, top panel) includes 23 nontumor, 42 grade II, 31 grade III, and 77
grade IV glioblastoma samples. The Stanford GEO Data Set (GSE2223, bottom panel) includes 4 normal brain, 5 grade II, 9 grade III, and
27 grade IV glioblastoma samples. Molecules analyzed are EWI-2 (IGSF8, PGRL) and EWI-F (PTGFRN, CD9P-1, FPRP, CD315). (B) EWI-2
protein expression is shown in sections of (c) and (f) human glioblastoma tumors (representative of samples from four different tumors)
and (e) normal human brain: c indicates cortex; w, white matter (representative of samples from three different brains). Control experi-
ments show absence of EWI-2 staining in (a) U87 tumor = t, implanted in mouse brain = b; and presence of EWI-2 in (d) U87–EWI-2–
transfected cells implanted in mouse brain; (b) negative control antibodies are used to show background staining in normal human
brain. (C) EWI-2 gene expression correlates with glioma patient survival. The Phillips data (GEO DataSet GSE4271) are MAS5 signal
intensities for 77 grade III and grade IV glioblastomas [60]. The Phillips data were divided based on EWI-2 MAS5 expression values
(probe set 225025_at) into above (n = 57, dashed line) or below (n = 20, solid line) first quartile groups. Censored data are indicated
by vertical ticks. P value is the log rank test probability. Note: MAS5 is a statistical algorithm developed by Affymetrix, Inc. to estimate
gene expression from array data, as described in a documentation available from Affymetrix.com.
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EWI-2 Causes Reorganization of Its Associated Cell Surface
Protein Complexes
Next, we sought to identify relevant molecular mechanisms to
help explain EWI-2 function. Initially, we focused on tetraspanins
CD9 and CD81 because 1) these molecules themselves may play
critical roles during gliomagenesis (see the introduction), 2) they as-
sociate closely with EWI-2, and 3) they are known to regulate cell
growth, migration, and invasion (see the introduction). For these
studies, we focused on plasma membrane organization of CD9 and
CD81 because this has been previously linked to EWI-2 function
[3,4] and correlated with tumor cell malignancy [17]. Immunopre-
cipitation of either CD9 or CD81 from surface biotin-labeled U87-
LucNeo cells yielded EWI-2 (Figure 4A). Hence, tetraspanin–EWI-2
complexes are present on the cell surface. Furthermore, the presence
of EWI-2 caused staining with anti-CD9 mAb C9BB to decrease by
∼70% relative to total CD9, stained by mAb MM2/57 (Figure 4B).
The mAb C9BB preferentially recognizes homoclustered CD9 [17].
Consequently, EWI-2 is causing CD9 to become reorganized into het-
eroclusters, as seen previously in other cell types [17]. Tetraspanin re-
organization could also be seen in immunoprecipitation experiments.
Recoveries of CD81 (on CD9 immunoprecipitation) and CD9 (on
CD81 immunoprecipitation) were markedly increased when EWI-2
was present in U87-LucNeo cells (Figure 4C). For example, as indi-
cated by densitometric scanning (Figure 4D), approximately three-
fold more CD81 associated with CD9, and approximately three-fold
more CD9 associated with CD81 when EWI-2 was present (com-
pare lanes 2 and 4 with lanes 1 and 3). Thus, the molecular orga-
nization of CD9 and CD81, with respect to neighboring proteins,
is substantially affected by the presence of EWI-2 in these cells. In
other experiments, we found that EWI-2 expression did not trigger
any detectable shedding of either CD9 or CD81-containing com-
plexes from intact cells into the growth media. In addition, EWI-2
expression did not affect tetraspanin internalization, during a 1- to
3-hour period, as assessed by monitoring the disappearance of cell
surface–bound antibodies.
For further mechanistic insight into EWI-2 effects on glioblas-
toma, we focused on MMP-2 because 1) pericellular proteolysis,
involving proteases such as MMP-2, plays a key role during glio-
blastoma invasion and survival [33–35] and 2) MMP-2 activation
is supported by tetraspanins CD9 and CD81 (M.L. et al., manu-
script submitted). On EWI-2 expression, there were no obvious
changes in secreted MMP-2 levels, from U87-MG cells, at three dif-
ferent time points in a gelatin zymogram assay (Figure 5A). However,
tetraspanin-associated MMP-2 was changed. Immunoprecipitation
Figure 2. In vivo tumor formation. (A) T98G cells (4 × 106 cells) were injected subcutaneously into nude mice (in two flanks, four mice
per cell line), and tumor sizes, (l)(w)(h)(0.52), were determined after 90 days. *P < .05 when EWI-2 samples are compared with vector
control results. P< .02 when EWI-2 samples are compared with pooled control experiments (vector control plus CD2 control), according
to Fisher exact test. (B) U87-LucNeo and U87-LucNeo/EWI-2 cells (50,000) were each injected intracranially into 10 nude mice and then
imaged after 14 days. (C) Three independent experiments were carried out as in (B), and tumor size was quantitated by in vivo bio-
luminescence imaging (*P < .05). Note that tumors were observed in 100% of vector control mice. The arbitrary units representing
photon flux values (y-axes) show interexperimental variability that may arise owing to the use of different stocks of luciferin, altered im-
aging parameters, altered size of the imaging area, or other variables. However, these parameters were carefully controlled intraexper-
imentally. (D) Cell surface expression of EWI-2 and control MHC class I in U87-LucNeo cells.
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Figure 3. EWI-2 effects on proliferation, soft agar colony formation invasion and migration. (A) Cell numbers were measured for U87-
LucNeo cells stably transduced with vector (open circles), or EWI-2 (closed squares). (B) The indicated cell lines expressing vector alone,
CD2 (another cell surface IgSF protein), or EWI-2 were plated (600 cells per well) in soft agar for 3 weeks, and then colonies were
counted (*P < .01 vs vector control cells). (C) U87-LucNeo cells, transduced with vector or EWI-2, were measured for chemotactic
migration and cell invasion (*P < .01; **P < .001).
Figure 4. EWI-2 affects cell surface molecular organization of CD9 and CD81. (A) Intact U87-LucNeo cells (expressing wild type EWI-2 or
vector control) were labeled with biotin and were then lysed. CD9, CD81, and EWI-2 were immunoprecipitated, and cell surface proteins
were visualized by blot analysis with ExtrAvidin. Note: EWI-2–associated CD9 and CD81 themselves do not label very well with biotin
because associated proteins limit accessibility (e.g., see Kolesnikova et al. [3]). (B) U87-LucNeo cells, expressing vector alone or EWI-2,
were incubated with mAb W6/32 (to MHC-I), mAb C9BB (which preferentially recognizes oligomerized CD9 [18], or mAb MM2/57 (which
recognizes total CD9). After washing, bound antibodies were visualized using fluorescein isothiocyanate–rabbit antimouse second anti-
body, and quantitated by flow cytometry. R= ratio of mean fluorescence intensities for C9BB divided by MM2/57. (C) U87-LucNeo cells,
expressing vector alone or EWI-2, were labeled with 3H-palmitate, lysed, and then CD9, CD81, and EWI-2 were immunoprecipitated.
Lower panels show an enlarged view of key regions from the top panel. The palmitoylation of EWI-2 on membrane proximal cysteines
will be described in more detail elsewhere. (D) Densitometric scans of lanes 1 to 4 are shown. Quantitation reveals increases of ap-
proximately three-fold in recovery of CD9 (in lane 4 vs 3) and CD81 (in lane 2 vs 1). Note: These results provide the first definitive dem-
onstration that EWI-2 is palmitoylated.
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of pooled tetraspanins (Figure 5C , lane 3) or CD81 alone (lane 4 )
from mild detergent lysates of U87-LucNeo cells yielded MMP-2
gelatinolytic activity. Recovery of this activity was diminished by
70% to 90% when EWI-2 was present (Figure 5C , lanes 7 and 8).
In additional experiments, MMP-2 activity associated with CD81
and CD9 was reduced by 13% to 57% in U87 cells (Figure 5B, com-
pare lanes 3 and 4 with 7 and 8) and by 43% to 71% in T98G cells
(Figure 5D, compare lanes 2 and 3 with 5 and 6 ) when EWI-2 was
present. Diminished MMP-2 activity was not caused by the de-
creased immunoprecipitation of CD9 or CD81. In fact, recovery
of CD9 and CD81 was typically increased when EWI-2 was present,
as seen by immunoblot analysis (Figure 5B, lower panels; Figure 5D,
not shown). Minimal amounts of MMP-2 were recovered on immu-
noprecipitation of CD147, an abundant cell surface protein that does
not associate with TEMs (Figure 5, B and C , lanes 2 and 6 ), or of
CD82, a tetraspanin that associates poorly with EWI-2 (Figure 5B,
lanes 5 and 9; Figure 5D, lanes 1 and 4 ).
We suspected that a subset of total MMP-2 may be linked to tet-
raspanins through membrane-bound protease MT1-MMP because
1) MT1-MMP can associate with CD9 and CD81 (M.L. et al., man-
uscript submitted) and 2) MMP-2 is known to form a complex with
MT1-MMP during MMP-2 activation [36]. Immunoprecipitation
of pooled tetraspanins (Figure 5E , lane 4 ) or CD81 alone (Figure 5E ,
lane 5 ) yielded MT1-MMP protein. However, when EWI-2 was
present in U87 cells, association of MT1-MMP with pooled tetra-
spanins was decreased by 45% (compare lane 4 with lane 7) and as-
sociation with CD81 was decreased by 75% (compare lane 5 with
lane 8). Meanwhile, in U87 cells, there was no decrease in either
the amount of total MT1-MMP (Figure 5E , lanes 9 and 10) or in
the amount of tetraspanin proteins (e.g., Figure 5B, lower panels).
In conclusion, results in this section show that EWI-2 markedly
reorganizes multiple molecules (CD9, CD81, MMP-2, MT1-MMP)
of likely importance during glioblastoma invasion and growth.
Discussion
EWI-2 protein and gene transcripts are abundant in normal brain
tissue and in primary astrocyte cultures. However, EWI-2 protein is
reduced in all glioblastoma tumors and cell lines analyzed, and EWI-2
transcripts are markedly reduced in glioblastoma and other gliomas, as
seen from the analysis of two independent human data sets. By con-
trast, transcripts corresponding to other EWI protein family members
are either strongly (EWI-F) or moderately (EWI-101, EWI-3) in-
creased in human glioma data sets, compared to normal brain. Loss
of EWI-2 expression is accompanied by diminished survival for grade
Figure 5. EWI-2 affects the molecular organization of MMP-2 and MT1-MMP. (A) Conditioned media were collected from U87-LucNeo
cells (± EWI-2) and assayed for MMP-2 levels using gelatin zymography. (B, C) U87-LucNeo cells (± EWI-2) were lysed, protein com-
plexes were immunoprecipitated, and associated MMP-2 levels were determined using gelatin zymography. TM4 = mixture of CD9,
CD63, CD81, CD82, and CD151. Numbers in parentheses indicate relative amounts of MMP-2 in corresponding lanes. Selected samples
(in B) were also analyzed for the presence of CD81 and CD9, as determined by Western blot analysis with M38 (CD81) and ALB6 (CD9)
antibodies (lower panels). (D) T98G cells (± EWI-2) were lysed and analyzed as in (B, C). Note: Zymograms in (B–D) are inverted to show
black on a white background. (E) U87-LucNeo cells (± EWI-2) were lysed, protein complexes were immunoprecipitated, and associated
MT1-MMP levels were determined by immunoblot analysis of the active form of MT1-MMP. MT1-MMP in total lysates was also blotted.
TM4 = mixture of CD9, CD63, CD81, CD82, and CD151. Numbers in parentheses indicate the relative amounts of MT1-MMP in the
corresponding lanes. MT1-MMP standards are from MCF-7 cell lysates with or without MT1-MMP expression.
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III and grade IV glioma patients. Furthermore, EWI-2 reexpression
abolished T98G ectopic (subcutaneous) tumor growth in vivo, and
considerably impaired intracranial U87-MG tumor growth in vivo,
in nude mice. EWI-2 expression in glioblastoma cell lines also inhibited
soft agar growth, invasion, and migration. These studies demonstrate
that EWI-2 may have tumor suppressor–like properties in preclinical
glioma models. However, the prognostic and clinical significance of
EWI-2 loss of function still needs to be evaluated prospectively.
The EWI-2 gene, which maps to 1q23.1, is not known to be spe-
cifically mutated or deleted in gliomas. Of possible relevance, partial
or complete 1q monosomies have been observed in a few adult astro-
cytomas [37], and 1q21-41 trisomy is associated with a worse prog-
nosis in pediatric anaplastic astrocytoma [37,38]. However, although
chromosome 1q alterations appear only in a minority of cases, EWI-2
expression is markedly diminished in most adult gliomas. Hence,
another mode of regulation, e.g., at the level of transcription, possibly
through promoter methylation, may play a major role. As a cell surface
transmembrane protein, EWI-2 is quite distinct from known glio-
blastoma tumor suppressors, which typically are intracellular molecules
involved in signaling or cell cycle regulation [39]. One other trans-
membrane protein that could serve as a glioma tumor suppressor is
coxsackie and adenovirus receptor (CAR). The expression of CAR is
markedly reduced in high-grade astrocytomas, and CAR diminishes
the size of U87-MG tumor xenografts [40].
Our in vitro studies provide several insights into the mechanism of
EWI-2 action. First, although EWI-2 did not inhibit glioblastoma
cell proliferation in two-dimensional culture, it significantly inhibited
soft agar growth, consistent with EWI-2 being antitumorigenic. Sec-
ond, EWI-2 caused a decrease in cell invasion and migration. This
helps to explain how EWI-2 could affect in vivo glioblastoma pro-
gression, which is a highly invasive process [34,35]. Rodent glioblas-
toma xenograft models are sometimes criticized for not recapitulating
invasive pathologic features of human glioblastoma multiforme (GBM)
[41]. However, GBM arising from implanted U87 cells does show his-
topathologic features compatible with tumor invasion into nonneoplas-
tic brain parenchyma [42]. EWI-2 inhibition of glioblastoma cell
invasion and migration is consistent with previously observed inhibi-
tory effects on motility, spreading, and ruffling in carcinoma and leu-
kemia cell lines [3–5].
Our biochemical studies provide mechanistic insights into EWI-2
functions in vivo and in vitro. We focused on molecules that 1) di-
rectly or indirectly associate with EWI-2 and 2) are known to affect
relevant functions of astrocytes and/or glioblastoma cells. Initially,
we focused on tetraspanin proteins CD9 and CD81. For CD9 and
CD81, EWI-2 (and EWI-F) are the most robust protein partners yet
described [2,43–45], and CD9 and/or CD81 are required for EWI-2
cell surface expression and maturation [4]. EWI-2 associated with
tetraspanins CD9 and CD81 on the surface of glioblastoma cells,
thereby disrupting CD9 homo-oligomers and enhancing formation
of CD9−CD81−EWI-2 complexes. Similar results have been seen
on the expression of EWI-2 in other cell types [3,4,17]. Such changes
could affect glioblastoma cell invasion and growth in multiple ways:
1) EWI-2 can cause redistribution of CD9 and CD81 to filopodia [4].
If a similar change occurs in glioblastoma, CD81 and CD9 would be
well positioned to modulate tumor cell expansion into brain paren-
chyma, especially because CD9 can affect the dynamics of filopodia
formation [46]. 2) Reorganization and redistribution of CD9 could
potentially be accompanied by rearrangement of CD9 partner mole-
cules, such as transforming growth factor α and heparin-binding EGF-
like growth factor, which play major roles during glioblastoma tumor
progression [6,11,12]. 3) Redistribution of CD9 and CD81 could
lead to altered localization and function of CD9 and CD81-associated
signaling molecules, such as protein kinase C [47] and PI 4-kinase
[48]. 4) Alterations in CD9 and CD81 organization could affect
the subcellular positioning and functions of integrins and other rele-
vant molecules. For example, EWI-2 can markedly affect CD9 and
CD81 colocalization with α3β1 integrin in filopodia [4]. In this regard,
α3β1 integrin also plays an important role during glioblastoma in-
vasion [49]. Also, other tetraspanin proteins such as CD151 [4] can
associate with EWI-2–CD9–CD81 complexes, and CD151 is upregu-
lated on glioblastoma cells (Figure W1 and [22]) and can stimulate
glioblastoma motility and invasion [50]. Hence, CD151 could play
an opposing role during inhibition of glioblastoma functions by over-
expressed EWI-2. Several additional genes have been shown to be dif-
ferentially expressed in correlation with GBM occurrence (e.g., [51])
and patient survival (e.g., [52]). It remains to be seen whether any of
these gene products act in coordination with EWI-2.
We also analyzed the effects of EWI-2 expression on key proteases
MMP-2 and MT1-MMP. Both are known to be involved in glio-
blastoma cell invasion, survival, and growth [33,35,53]. MT1-MMP
promotes tumor growth by disrupting three-dimensional matrix
growth control exerted on tumors [54]. On expression of EWI-2, total
protein levels of MMP-2 and MT1-MMP were unaltered. However,
there was a substantial decrease in both the amount of MMP-2 activity
and the amount of MT1-MMP protein recovered in association with
tetraspanin complexes. We show elsewhere that MT1-MMP can asso-
ciate with tetraspanins CD9 and CD81 (M.L. et al., manuscript sub-
mitted). Although tetraspanin CD151 was not a prominent partner
for MT1-MMP on glioblastoma cells (M.L. et al., manuscript sub-
mitted), CD151–MT1-MMP association was seen on endothelial cells
[55]. During MMP-2 activation, it forms a complex with MT1-MMP
and TIMP-2 [36]. The existence of this complex helps to explain the
parallel dissociation of MMP-2 and MT1-MMP from tetraspanins
on EWI-2 expression. Our current model is that MMP-2−MT1-
MMP complexes associate preferentially with homo-oligomeric CD9
and/or CD81. When EWI-2 is present, there is a shift toward hetero-
oligomeric complexes [17], accompanied by MMP dissociation (as
shown here). If EWI-2 is disrupting MMP complexes, while driving
CD81 and CD9 into the filopodia [4], this would likely influence
glioblastoma invasion, survival, and/or growth. However, it remains
to be determined whether EWI-2 causes reorganization of MMPs
within filopodia.
Another possibility is that EWI-2 inhibition of glioblastoma de-
pends on EWI-2 interaction with a counter-receptor. So far, we have
failed to identify potential counter-receptor activity, or specific counter-
receptors, on astrocytoma cells. Nonetheless, a possible contribution by
a counter-receptor cannot be ruled out.
In conclusion, we find that EWI-2 levels are considerably dimin-
ished in human glioblastoma samples in association with diminished
patient survival. Furthermore, reexpression of EWI-2 in glioblastoma
cell lines leads to impaired tumor growth in vivo, in both ectopic and
orthotopic models. EWI-2 seems to function, at least in part, by ex-
tensively reorganizing CD9 and CD81 protein complexes. This is
likely accompanied by concurrent reorganization of additional other
CD9 and CD81 partner proteins (e.g., proteases, adhesion recep-
tors, signaling molecules), thus leading to suboptimal glioblastoma
growth, invasion, and motility. Finally, we speculate that the tumor
suppressor effects of CD9 observed on several non–glioma tumor
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types [56–58] could, to a large extent, involve inhibitory effects of
EWI-2, which is CD9’s major partner protein.
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Figure W1. Expression of EWI proteins and tetraspanins in normal brain and in grade IV astrocytoma. Data shown are from the Stanford
GEO DataSet GSE2223, analyzed as in Figure 1A, bottom panel. Molecules analyzed are EWI-3 (IGSF3), EWI-101 (CD101), CD9, CD81,
and CD151. Similar results were obtained on analysis of these same molecules in the Henry Ford GEO Data Set (GSE4290, used in Fig-
ure 1A, top panel; not shown).
Figure W2. EWI-2 expression in diverse human tissues and organs. Multiple tissue expression array (Clontech, Mountain View, CA) was
hybridized with EWI-2 probe or ubiquitin probe. Relative expression level of EWI-2 after normalization for ubiquitin probe is shown.
Figure W3. EWI-2 expression by normal human astrocytes. Normal human astrocytes (Lonza, Walkersville, Inc) were cell surface–labeled
with biotin, lysed in 1% NP-40 and then MHC I (mAb W6/32) and EWI-2 (polyclonal antibody) were immunoprecipitated. Proteins were
resolved by 10% SDS-PAGE and then blotted (A) using anti–EWI-2 mAb 8A12 to detect total immunoprecipitated EWI-2 or (B) ExtrAvidin to
detect surface-biotinylated EWI-2. (C) Control cell lysates from U87, T98G, T98G−EWI-2, and U937 cells were blotted using anti–EWI-2
mAb 8A12.
Figure W4. Cell surface expression of EWI-2 and control cell surface antigens (CD98, MHC class I, or CD9) in glioblastoma (A) and other
cell lines (B). Cell lines used were glioblastoma cell lines T98G, U87 MG, U118 MG, and LN827-LucNeo, as well as Molt 4 (T cell leu-
kemic cell line) and HeLa (ovarian carcinoma). Numbers next to peaks indicate mean fluorescence intensities.
Table W1. Summary of EWI-2 Expression Data.
Experiment Normal Brain Glioblastoma
RNA expression (Henry Ford GEO Data Set;
Figure 1A, top panel )
++ −
RNA expression (Stanford GEO Data Set;
Figure 1A, bottom panel )
++ −
RNA expression (Figure W2) ++ ND
RNA in developing mouse brain [29] ++ ND
RNA in adult mouse brain [31] ++ ND
Protein staining (IHC; Figure 1B) ++ (n = 3) − (n = 4)
Protein on surface of human GBM cell
lines (Figure W4)
ND − (n = 4)
Protein in human GBM cell lysates
(Figure W3C )
ND − (n = 2)
Protein in primary human astrocytes
(Figure W3, A and B)
++ ND
Protein in mouse brain [30] ++ ND
IHC indicates immunohistochemistry; ND, Not Determined
Figure W5. EWI-2 expression correlates with patient survival for
both Grade III and grade IV glioblastomas. Data are analyzed exactly
as in Figure 1C , except that grade III and grade IV glioblastomas are
now analyzed separately, instead of being pooled. For grade III re-
sults, P = .27; for grade IV, P = .057. As indicated in Figure 1C for
pooled results, P = .041.
Figure W6. U87-LucNeo (A–D) and U87-LucNeo/EWI-2 (E–H) cells were injected intracranially as in Figure 1C . After 35 days, serial brain
sections were obtained, starting from the injection point. All images show hematoxylin and eosin staining at 4× magnification. Sections
are shown from four representative mice injected with U87-LucNeo control cells (top row) and four representative mice injected with
U87-LucNeo/EWI-2 cells (bottom row). b indicates brain; t, tumor; v, ventricle.
